TY - JOUR
TI - A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece – the ‘APRAISAL’ study
AU - Ioannides, D.
AU - Antonakopoulos, N.
AU - Chasapi, V.
AU - Oikonomou, C.
AU - Tampouratzi, E.
AU - Lazaridou, E.
AU - Rigopoulos, D.
AU - Neofotistou, O.
AU - Drosos, A.
AU - Anastasiadis, G.
AU - Rovithi, E.
AU - Kalinou, C.
AU - Papadavid, E.
AU - Aronis, P.
AU - Papageorgiou, M.
AU - Protopapa, A.
AU - Bassukas, I.
AU - Lefaki, I.
AU - Zafiriou, E.
AU - Krasagakis, K.
AU - Pokas, E.
AU - Anagnostopoulos, Z.
AU - Kekki, A.
AU - Papakonstantis, M.
JO - Journal of the European Academy of Dermatology and Venereology
PY - 2022
VL - null
TODO - null
SP - null
PB - John Wiley and Sons Inc
SN - 0926-9959, 1468-3083
TODO - 10.1111/jdv.18166
TODO - null
TODO - Background: Real-world data in patients with moderate psoriasis treated with apremilast is limited. Objectives: To evaluate the effectiveness and safety of apremilast in bio-naïve patients with moderate psoriasis in real-world clinical settings. Methods: This was a 52-week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment. Missing data were imputed using the last observation carried forward method. Results: A total of 287 eligible patients (median age: 54.2 years; median psoriasis duration: 9.8 years) were consecutively enrolled. At baseline, the median DLQI and PASI scores were 12.0 and 11.8, respectively. The 52-week DLQI ≤ 5 and PASI75 response rates were 68.3% and 61.0%. At 52 weeks, 70.8% and 72.7% of the patients shifted from moderate/severe/very severe to clear/minimal scalp and palmoplantar psoriasis involvement, respectively; the pruritus severity state improved in 67.2%. The 52-week Kaplan–Meier estimated drug continuation rate was 85.3%. The adverse drug reaction rate was 19.9%. Conclusions: Apremilast is a safe and effective treatment for bio-naïve patients with moderate psoriasis and specific psoriasis manifestations. © 2022 European Academy of Dermatology and Venereology.
ER -